We are international
Donate
TEXT SIZE   


Myeloma Canada Seeks US Patient and Caregiver Input

The survey is about your experience with carfilzomib (Kyprolis®). Your help with this important matter is greatly appreciated, as we do not have Canadian patients, outside of a limited number of clinical trials, who have used the treatment this way.

09.16.15

Once again, Myeloma Canada is reaching out to US myeloma patients and caregivers to take a few minutes to complete a brief online survey by clicking this link.

The survey is about your experience with carfilzomib (Kyprolis®). Your help with this important matter is greatly appreciated, as we do not have Canadian patients, outside of a limited number of clinical trials, who have used the treatment this way.

In Canada, carfilzomib (Kyprolis®) in combination with lenalidomideand dexamethasone is under review for treatment of patients with multiple myeloma who have received at least one prior therapy. As part of the review process, patient groups such as Myeloma Canada are invited to provide input so that patients and caregivers can be heard.

Previously, we have conducted similar surveys for other myeloma treatments. We were fortunate to receive considerable support from US patients and caregivers who participated in our surveys. The Canadian reviewers have valued our combined input and positive funding decisions were made.

Your feedback is extremely important and, although there is no guarantee, may help to improve access to this drug for patients across Canada.

Please join us and have your say. This is a short survey; it should take less than 10 minutes. We ask that you complete the survey by Friday, October 7, 2015.

Link to the survey : https://www.surveymonkey.com/r/MyelomaCanPatientCaregiverSurveySep15Oct72015

Thank you,

Francine Gendron
Myeloma Canada Chief Executive Officer

Privacy Policy: All survey data are being collected by Myeloma Canada, a nationally registered patient-led group identified by pCODR (the agency conducting the review) for this submission. To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other identifying information.


 related articles